Bayer has acquired rights to Cytokinetics' heart drug in Japan through a collaboration deal. The agreement includes an upfront payment of 50 million euros with potential additional payments based on development and sales milestones, totaling up to 580 million euros.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing